ArticleMolecular therapy. Nucleic acids2022

Benefits of therapy by dynamin-2-mutant-specific silencing are maintained with time in a mouse model of dominant centronuclear myopathy.

Delphine Trochet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.